Navigation Links
Study shows ultrasound and tPA effective for stroke
Date:2/19/2009

BIRMINGHAM, Ala. An experimental therapy using tiny bubbles activated by transcranial Doppler (TCD) ultrasound combined with the clot busting drug tissue plasminogen activator (tPA) is more effective than tPA alone in treating patients suffering from ischemic stroke, according to new research presented at the American Stroke Association's International Stroke Conference in San Diego.

The findings, presented by Andrei Alexandrov, M.D., director of the UAB (University of Alabama at Birmingham) Comprehensive Stroke Center, and Carlos Molina, M.D., of the Vall d'Hebron Hospital in Barcelona, Spain, show that patients can be treated safely with TCD in combination with a specific dose of the bubbles, called microspheres, and tPA.

The microspheres, developed by ImaRx Therapeutics, are tiny gas-filled lipid structures that cavitate (rapidly expand and collapse) when exposed to ultrasound waves, helping to reopen blocked arteries and restore blood flow.

"These findings demonstrate that ultrasound combined with microspheres and tPA can be tested further in a pivotal clinical trial with the goal of providing a more effective treatment option for stroke patients by promoting faster clearing of blocked blood vessels as well as improved patient outcomes," said Alexandrov, UAB professor of neurology. "It's very promising to see such results, which support the potential of this therapy as a more effective and expansive therapy for stroke patients."

The Phase 1/2 trial involved 35 patients and evaluated two different doses of ImaRx's MRX-801 microspheres. Cohort I and cohort II patients received 1.4 mL and 2.8 mL of microspheres respectively. Control patients received the standard dose of tPA alone.

The researchers report that complete recanalization was achieved in 120 minutes in 67 percent of cohort I patients, in 46 percent of cohort II patients and 33 percent of control patients. Dramatic clinical recovery has achieved in 45 percent of cohort I, 10 percent of cohort II and 27 percent of controls.

In addition, clinical improvement after 90 days was reported in 75 percent of cohort I, 50 percent of cohort II and 36 percent of controls.

According to the American Heart Association, approximately one-third of adults in the United States have some form of cardiovascular disease. Approximately 700,000 adults in the U.S., are afflicted with, and 150,000 die as a result of, some form of stroke each year.

Stroke is the third leading cause of death, and the leading cause of disability, in the United States. The vast majority of strokes are ischemic strokes, meaning that they are caused by blood clots, while the remainder are the more deadly hemorrhagic strokes caused by bleeding in the brain.


'/>"/>

Contact: Bob Shepard
bshep@uab.edu
205-934-8934
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. New Study Suggests Beta-Carotene Supplementation May Help Preserve Cognition in Men
2. JAMA article contends earlier study overstated validity of findings on bisphenol A
3. New iPod listening study shows surprising behavior of teens
4. Study calls for increased research in flu transmission to prepare for pandemic flu outbreak
5. Statins Pay Off on a Health-Policy Level, UCSF Study Finds
6. Major study on DiagnoCures GCC biomarker published in Jama
7. Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
8. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
9. New Study Shares Benchmarks for Medical Science Liaisons: Gaining Access and Forging Relationships with Key Opinion Leaders
10. Study finds that using wakefulness tests to detect daytime sleepiness in drivers may be unreliable
11. Study finds behavioral link between insomnia and tension-type headaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Featured ... provide a unique keynote address at the 2016 Learning Summit , June ... five community college students. Their stories—of complicated family issues, financial difficulties, and other ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ... offering for global clients of Coupa ( Coupa Software ) and other Cloud ... is a key component in the suite of innovative implementation services offered by ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with ... when the weather is too cold, dry or hot, water on the eye surface ... absorb moisture from the surrounding air. There’s only one problem, according to radio show ...
(Date:5/6/2016)... ... May 06, 2016 , ... From the Speaker Podium to the Exhibit Floor ... its insights on managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 ... deliver a Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction ...
(Date:5/6/2016)... ... May 06, 2016 , ... Expert ... . , Since launching in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com ... now include pillows, sheets, mattress toppers, bed frames, and more. , Founder and ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... of the  "Europe Systemic Lupus Erythematosus Market ... to their offering.       (Logo: ... latest research Europe Systemic Lupus Erythematosus Market ... comprehensive insights into Systemic Lupus Erythematosus pipeline ...
(Date:5/4/2016)... 2016  It,s time for an upgrade. There are many medical recorders on the ... LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a ... class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
Breaking Medicine Technology: